Public Company News
Gravitas Education Holdings, Inc. Announces Expected Timing for the Effective Time of the Merger
BEIJING, Dec. 12, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. (the "Company") (NYSE: GEHI) announced that the effective time of the merger between Bright Sunlight Limited, aCayman Islands exempted company and a direct, wholly owned subsidiary of the Company (the "Merger Sub") and Elmtr...
2023-12-12 18:00
3809
Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held inSan Diego, California from December 9-12. The data showcased updated results of Dizal's ...
2023-12-12 18:00
2757
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
* Identified as a global sustainability leader by S&P Global * Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), an...
2023-12-12 17:00
3458
Yum China to Report Fourth Quarter and Fiscal Year 2023 Financial Results
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Yum China Holdings, Inc. (NYSE: YUMC and HKEX: 9987, "Yum China" or the "Company") today announced that it will report its unaudited financial results for the fourth quarter and fiscal year endingDecember 31, 2023 at 4:30 p.m. U.S. Eastern Time on Tuesday, ...
2023-12-12 17:00
3911
MoonFox Data: JD.com Q3 profits exceeded expectations and the "low prices & supply chain" combo approach showed initial effectiveness
CHENGDU, China, Dec. 12, 2023 /PRNewswire/ -- About us: Aurora Mobile (NASDAQ: JG) established in 2011, is a leading customer engagement and marketing technology service provider inChina. Its business includes notification services, marketing growth, development tools, and data products. As its ...
2023-12-12 15:20
3518
MINISO Group Gives Updates on Increase Plan in Shareholding by Management
GUANGZHOU, China, Dec. 11, 2023 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global value retailer offering a variety of trendy lifestyle products featuring IP design, today announced that Mr. Zhang Jingjing, the Company's Ch...
2023-12-12 12:15
2813
Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety
SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (A...
2023-12-12 09:41
3454
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of$50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an...
2023-12-12 05:30
3171
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
2023-12-11 22:30
2996
Hollysys to be Acquired by Ascendent Capital Partners for US$26.50 in Cash Per Share
* Hollysys Board has unanimously approved Ascendent's all cash offer at 42% premium to the unaffected price as of23 August 2023 * Agreement marks culmination of formal sale process conducted by Special Committee of independent directors BEIJING, Dec. 11, 2023 /PRNewswire/ -- Hollysys Automati...
2023-12-11 22:10
4511
Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"),...
2023-12-11 21:00
3512
WiMi Developed Holographic Complex Amplitude Computation and Update Technology
BEIJING, Dec. 11, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it successfully developed a new technology----"Holographic Complex Amplitude Computation and Updat...
2023-12-11 21:00
2838
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...
2023-12-11 20:00
2800
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...
2023-12-11 20:00
2152
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering - 70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors - Demonstrated a confirmed objecti...
2023-12-11 18:55
2430
Qudian Inc. Reports Third Quarter 2023 Unaudited Financial Results
XIAMEN, China, Dec. 11, 2023 /PRNewswire/ -- Qudian Inc. ("Qudian" or "the Company" or "We") (NYSE: QD), a consumer-oriented technology company, today announced its unaudited financial results for the quarter endedSeptember 30, 2023. Third Quarter 2023 Financial Highlights: * Total revenues w...
2023-12-11 18:00
4246
Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib
SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...
2023-12-11 13:30
2255
Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety...
2023-12-11 13:14
2263
Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the clinical data of lisaftocl...
2023-12-11 12:56
1841
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published inThe Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Ex...
2023-12-10 18:00
3244
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
56335
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
49420
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
48475
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
29895
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
18324
